头孢哌酮钠舒巴坦钠联合甲硝唑治疗慢性盆腔炎的临床疗效及对盆腔炎性包块大小的影响

Clinical Efficacy of Cefoperazone Sodium and Sulbactam Sodium Combined with Metronidazole in the Treatment of Chronic Pelvic Inflammatory Disease and its Effect on the Size of Pelvic Inflammatory Mass

目的研究头孢哌酮钠舒巴坦钠(CSSS)联合甲硝唑治疗慢性盆腔炎的临床疗效及对盆腔炎性包块大小的影响。方法选取2020年12月-2023年3月峡江县中医院收治的62例慢性盆腔炎患者,经随机数字表法分为对照组(31例)和观察组(31例)。对照组给予头孢他啶联合甲硝唑治疗,观察组给予CSSS联合甲硝唑治疗,比较两组临床疗效、盆腔炎性包块面积、疼痛程度[视觉模拟评分(VAS)]、症状改善情况(下腹坠胀、白带增多、宫体压痛)、炎性指标[白细胞计数(WBC)、中性粒细胞比例(NEUT%)、C反应蛋白(CRP)]、复发情况。结果观察组治疗总有效率为96.77%,高于对照组的83.87%(P<0.05);两组治疗后盆腔炎性包块面积、VAS评分均小于治疗前,且观察组治疗后盆腔炎性包块面积、VAS评分小于对照组(P<0.05);两组治疗后症状评分(下腹坠胀、白带增多、宫体压痛)低于治疗前,且观察组治疗后症状评分(下腹坠胀、白带增多、宫体压痛)低于对照组(P<0.05);两组治疗后WBC、NEUT%、CRP指标低于治疗前,且观察组治疗后WBC、NEUT%、CRP指标低于对照组(P<0.05);治疗后6个月,观察组复发率低于对照组(P<0.05)。结论CSSS联合甲硝唑治疗慢性盆腔炎效果良好,可缩小患者盆腔炎性包块,缓解其疼痛程度,减轻临床症状,下调炎症指标,降低复发风险。

Objective To study the clinical efficacy of ceftazidime or cefoperazone sodium and sulbactam sodium(CSSS)combined with metronidazole in the treatment of chronic pelvic inflammatory disease and its impact on the size of pelvic inflammatory masses.Methods A total of 62 patients with chronic pelvic inflammatory disease admitted to Xiajiang County Hospital of Traditional Chinese Medicine from December 2020 to March 2023 were selected and divided into control group(31 patients)and observation group(31 patients)by random number table method.The control group was treated with ceftazidime combined with metronidazole,and the observation group was treated with CSSS combined with metronidazole.The clinical efficacy,pelvic inflammatory mass area,pain degree[Visual Analogue Scale(VAS)],symptom improvement(lower abdominal bulge,leucorrhea increase,uterine tenderness),inflammatory index[white blood cell count(WBC),neutrophil ratio(NEUT%),C-reactive protein(CRP)]and recurrence were compared between the two groups.Results The total effective rate of treatment in the observation group was 96.77%,which was higher than 83.87%in the control group(P<0.05).After treatment,the area of pelvic inflammatory mass and VAS score in the two groups were smaller than those before treatment,and the area of pelvic inflammatory mass and VAS score in the observation group were smaller than those in the control group(P<0.05).After treatment,the symptom scores(lower abdominal bulge,leukorrhea increase,uterine body tenderness)of the two groups were lower than those before treatment,and the symptom scores(lower abdominal bulge,leukorrhea increase,uterine body tenderness)of the observation group were lower than those of the control group(P<0.05).The WBC,NEUT%and CRP indexes of the two groups after treatment were lower than those before treatment,and the WBC,NEUT%and CRP indexes of the observation group after treatment were lower than those of the control group(P<0.05).At 6 months after treatment,the recurrence rate of the observation group was lower than that of the control group(P<0.05).Conclusion CSSS combined with metronidazole is effective in the treatment of chronic pelvic inflammatory disease,which can reduce the pelvic inflammatory mass,relieve the pain degree,reduce the clinical symptoms,down-regulate the inflammatory index and reduce the risk of recurrence.